Role of Denosumab in Spinal Giant Cell Tumour
International Journal of Orthopaedic Surgery · 2024
DOI: 10.4103/ijors.ijors_14_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Orthopaedic Surgery, 2024. Verfasst von Susmit Naskar. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Giant cell tumour (GCT) of bone (GCTB) is a type of giant cell-rich bone lesion specified by the presence of numerous multinucleated osteoclast-type giant cells. Giant cells are known to express receptor activator of nuclear factor-kappa B ligand (RANKL) and are responsible for the aggressive osteolytic nature of the tumour. No available treatment option is definitively effective in curing this disease, especially in surgically unsalvageable cases. Denosumab is a fully human monoclonal antibody that targets and binds with high affinity and specificity to RANKL. Results from the studies suggest that denosumab is potentially effective treatment for patients with GCTB of the spine, including the sacrum. This study is a review to highlight role of denosumab in spinal GCT.
Zitieren
APA
Naskar, S. (2024). Role of Denosumab in Spinal Giant Cell Tumour. International Journal of Orthopaedic Surgery. https://doi.org/10.4103/ijors.ijors_14_24
Vancouver
Naskar S. Role of Denosumab in Spinal Giant Cell Tumour. International Journal of Orthopaedic Surgery. 2024. doi:10.4103/ijors.ijors_14_24
BibTeX
@article{Naskar2024,
author = {Naskar, Susmit},
title = {Role of Denosumab in Spinal Giant Cell Tumour},
journal = {International Journal of Orthopaedic Surgery},
year = {2024},
doi = {10.4103/ijors.ijors_14_24}
}
EUVIMED